Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹15,761 Cr
P/E Ratio
48.31
P/B Ratio
9.47
Industry P/E
48.31
Debt to Equity
0
ROE
21.88 %
ROCE
29.13 %
Div. Yield
0.58 %
Book Value
159.1
EPS
31.19
CFO
₹1,158.65 Cr
EBITDA
₹2,325.05 Cr
Net Profit
₹1,612.17 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Concord Biotech
| -31.83 | -8.88 | -28.64 | -0.02 | -- | -- | -- |
|
BSE Healthcare
| -6.43 | 4.61 | 3.02 | 20.43 | 23.72 | 22.98 | 9.89 |
|
BSE Mid Cap
| -4.44 | 10.06 | 8.68 | 7.65 | 26.66 | 30.79 | 15.56 |
|
2024
|
|
|---|---|
|
Concord Biotech
| 49.44 |
|
BSE Mid Cap
| 25.84 |
|
BSE Healthcare
| 43.09 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,180.90 | 14,477.60 | 32.78 | 18.14 | |
| 770.15 | 13,362.04 | 43.78 | 29.67 | |
| 1,055.60 | 20,045.44 | 40.24 | 19.45 | |
| 12,474.00 | 16,001.82 | 53.36 | 17.92 |
4 min read•By Vishal Goyal
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical... ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India. Read more
Incorporated
1984
Chairman
Sudhir Vaid
Managing Director
Sudhir Vaid
Headquarters
Ahmedabad Dist, Gujarat
Website
Looking for more details about Concord Biotech Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Concord Biotech Ltd stood at ₹ 1,764 Cr as on 31-Dec-24
The share price of Concord Biotech Ltd is ₹1,507.00 (NSE) and ₹1,499.35 (BSE) as of 14-May-2025 IST. Concord Biotech Ltd has given a return of -0.02% in the last 1 years.
Concord Biotech Ltd has a market capitalisation of ₹ 15,761 Cr as on 14-May-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Concord Biotech Ltd is 9.47 times as on 14-May-2025, a 196% premium to its peers’ median range of 3.20 times.
The P/E ratio of Concord Biotech Ltd is 48.31 times as on 14-May-2025, a 0% premium to its peers’ median range of 48.31 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Concord Biotech Ltd and enter the required number of quantities and click on buy to purchase the shares of Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
The promoters of Concord Biotech Ltd are Sudhir Vaid and Manju Vaid. They collectively own 38.39 per cent of the total equity. The chairman of the company is Sudhir Vaid
There is no promoter pledging in Concord Biotech Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
19,140
|
|
|
15,954
|
|
|
13,660
|
|
|
12,594
|
| Concord Biotech Ltd | Ratios |
|---|---|
|
Return on equity(%)
|
20.93
|
|
Operating margin(%)
|
36.42
|
|
Net Margin(%)
|
28.92
|
|
Dividend yield(%)
|
0.58
|
Yes, TTM profit after tax of Concord Biotech Ltd was ₹326 Cr.
₹1.30
(
